168 related articles for article (PubMed ID: 25170113)
21. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.
Keller A; Wingelhofer B; Peter B; Bauer K; Berger D; Gamperl S; Reifinger M; Cerny-Reiterer S; Moriggl R; Willmann M; Valent P; Hadzijusufovic E
Vet Comp Oncol; 2018 Mar; 16(1):55-68. PubMed ID: 28397975
[TBL] [Abstract][Full Text] [Related]
22. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
Waight JD; Banik D; Griffiths EA; Nemeth MJ; Abrams SI
J Biol Chem; 2014 May; 289(22):15642-52. PubMed ID: 24753251
[TBL] [Abstract][Full Text] [Related]
23. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
[No Abstract] [Full Text] [Related]
24. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Wang XY; Sun GB; Wang YJ; Yan F
Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163
[TBL] [Abstract][Full Text] [Related]
25. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Wang Y; Cai D; Brendel C; Barett C; Erben P; Manley PW; Hochhaus A; Neubauer A; Burchert A
Blood; 2007 Mar; 109(5):2147-55. PubMed ID: 17090651
[TBL] [Abstract][Full Text] [Related]
26. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
[No Abstract] [Full Text] [Related]
27. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
[TBL] [Abstract][Full Text] [Related]
28. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
29. The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients.
Putri A; Rinaldi I; Louisa M; Koesnoe S
Acta Med Indones; 2019 Oct; 51(4):348-352. PubMed ID: 32041920
[TBL] [Abstract][Full Text] [Related]
30. Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Green MR; Newton MD; Fancher KM
Am J Clin Oncol; 2016 Feb; 39(1):76-84. PubMed ID: 24351780
[TBL] [Abstract][Full Text] [Related]
31. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
32. Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Li Y; Yang L; Pan Y; Yang J; Shang Y; Luo J
Oncol Rep; 2014 May; 31(5):2438-46. PubMed ID: 24647617
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
34. Targeted signal transduction therapies in myeloid malignancies.
Scott E; Hexner E; Perl A; Carroll M
Curr Oncol Rep; 2010 Nov; 12(6):358-65. PubMed ID: 20809224
[TBL] [Abstract][Full Text] [Related]
35. Haematological cancer: Deep molecular response predicts survival in CML.
Razzak M
Nat Rev Clin Oncol; 2014 Feb; 11(2):68. PubMed ID: 24343665
[No Abstract] [Full Text] [Related]
36. Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Trécul A; Morceau F; Gaigneaux A; Orsini M; Chateauvieux S; Grandjenette C; Dicato M; Diederich M
Cancer Lett; 2013 Oct; 340(1):30-42. PubMed ID: 23811288
[TBL] [Abstract][Full Text] [Related]
37. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
38. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
39. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
[TBL] [Abstract][Full Text] [Related]
40. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
